VERA

Vera Therapeutics, Inc. (VERA) ESG Analysis Analysis (2026)

Invetso Score: 5.2/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Environmental

No material environmental disclosures or ESG-specific updates were provided in the fresh data.

The company remains assessed primarily on financial resilience rather than reported environmental initiatives or liabilities.

Social

No new social, labor, or customer-related developments were reported in recent news.

There is insufficient fresh evidence to change the prior neutral assessment of social factors.

Governance

The company continues to show strong liquidity with a current ratio of 10.9 and cash ratio of 1.01, supporting governance-related financial stability.

Leverage remains modest with debt-to-equity of 0.18 and debt-to-assets of 0.14, but profitability and cash flow remain negative, which limits the overall governance quality assessment.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →